Literature DB >> 32056202

STIM1 knock-down decreases the affinity of obinutuzumab for CD20 by altering CD20 localization to Triton-soluble membrane.

W Heo1, N Jin1, M S Park1, H-Y Kim1, S M Yoon2, J Lee2, J Y Kim1.   

Abstract

Obinutuzumab is thought to exert its effects through its high antibody-dependent cellular cytotoxicity (ADCC) via glyco-engineering of the Fc region. In addition, obinutuzumab causes direct binding-induced cell death (DCD) only by specifically binding to its target CD20, a Ca2+ channel. However, the specific features of CD20 related to obinutuzumab binding-induction of cell death are not clearly understood. In this study, we evaluated the relationship between the Ca2+ channel features of CD20 as a store-operated Ca2+ channel (SOC) and obinutuzumab binding-induced cell death. Ca2+ channel function and biochemical analysis revealed that CD20 is an Orai1- and stromal interaction molecule (STIM1)-dependent Ca2+ pore. However, binding of obinutuzumab on CD20 did not have any effect on Ca2+ influx activity of CD20; the direct cell death rate mediated by obinutuzumab binding was almost equivalent with or without the extracellular Ca2+ condition. Given the apparent interaction between STIM1 and CD20, we observed Triton-X solubilized obinutuzumab-bound CD20 accompanied by STIM1. Subsequently, obinutuzumab binding and cell death were decreased by STIM1 knock-down in Ramos B cells. Thus, STIM1 directly contributes to cell death by increasing the affinity of cells for obinutuzumab by transferring CD20 to the Triton-soluble membrane region.
© 2020 British Society for Immunology.

Entities:  

Keywords:  CD20; Ca2+; STIM1; direct binding-induced cell death; obinutuzumab; raft

Mesh:

Substances:

Year:  2020        PMID: 32056202      PMCID: PMC7232002          DOI: 10.1111/cei.13427

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  36 in total

1.  Store-operated cation entry mediated by CD20 in membrane rafts.

Authors:  Haidong Li; Linda M Ayer; Jonathan Lytton; Julie P Deans
Journal:  J Biol Chem       Date:  2003-08-14       Impact factor: 5.157

2.  The CD20 calcium channel is localized to microvilli and constitutively associated with membrane rafts: antibody binding increases the affinity of the association through an epitope-dependent cross-linking-independent mechanism.

Authors:  Haidong Li; Linda M Ayer; Maria J Polyak; Cathlin M Mutch; Ryan J Petrie; Laura Gauthier; Neda Shariat; Michael J Hendzel; Andrew R Shaw; Kamala D Patel; Julie P Deans
Journal:  J Biol Chem       Date:  2004-02-19       Impact factor: 5.157

Review 3.  CD20 as a target for therapeutic type I and II monoclonal antibodies.

Authors:  Stephen A Beers; Claude H T Chan; Ruth R French; Mark S Cragg; Martin J Glennie
Journal:  Semin Hematol       Date:  2010-04       Impact factor: 3.851

Review 4.  Mechanisms of killing by anti-CD20 monoclonal antibodies.

Authors:  Martin J Glennie; Ruth R French; Mark S Cragg; Ronald P Taylor
Journal:  Mol Immunol       Date:  2007-09       Impact factor: 4.407

5.  Activatory and inhibitory Fcγ receptors augment rituximab-mediated internalization of CD20 independent of signaling via the cytoplasmic domain.

Authors:  Andrew T Vaughan; Claude H T Chan; Christian Klein; Martin J Glennie; Stephen A Beers; Mark S Cragg
Journal:  J Biol Chem       Date:  2015-01-07       Impact factor: 5.157

Review 6.  Endoplasmic Reticulum-Plasma Membrane Contact Sites.

Authors:  Yasunori Saheki; Pietro De Camilli
Journal:  Annu Rev Biochem       Date:  2017-02-23       Impact factor: 23.643

7.  Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.

Authors:  Guillaume Cartron; Sophie de Guibert; Marie-Sarah Dilhuydy; Franck Morschhauser; Veronique Leblond; Jehan Dupuis; Beatrice Mahe; Reda Bouabdallah; Guiyuan Lei; Michael Wenger; Elisabeth Wassner-Fritsch; Michael Hallek
Journal:  Blood       Date:  2014-08-20       Impact factor: 22.113

8.  Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies.

Authors:  Gerhard Niederfellner; Alfred Lammens; Olaf Mundigl; Guy J Georges; Wolfgang Schaefer; Manfred Schwaiger; Andreas Franke; Kornelius Wiechmann; Stefan Jenewein; Jerry W Slootstra; Peter Timmerman; Annika Brännström; Frida Lindstrom; Ekkehard Mössner; Pablo Umana; Karl-Peter Hopfner; Christian Klein
Journal:  Blood       Date:  2011-03-28       Impact factor: 22.113

9.  Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1 (CD20) antigen, and localization of the gene to chromosome 19.

Authors:  T F Tedder; G Klejman; C M Disteche; D A Adler; S F Schlossman; H Saito
Journal:  J Immunol       Date:  1988-12-15       Impact factor: 5.422

Review 10.  Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.

Authors:  Mitchell R Smith
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.